Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition and Contractual Adjustments (Tables)

v3.20.2
Revenue Recognition and Contractual Adjustments (Tables)
6 Months Ended
Jun. 30, 2020
Revenue from Contract with Customer [Abstract]  
Summary of Contract Assets and Liabilities
The following table summarizes the values of contract assets, capitalized commissions and contract liabilities as of June 30, 2020 and December 31, 2019 (in thousands):

June 30, 2020 December 31, 2019
Current pharma contract assets (1)
$ 1,255    $ 1,000   
Long-term pharma contract assets (2)
221    153   
Total pharma contract assets $ 1,476    $ 1,153   
Current pharma capitalized commissions (1)
$ 183    $ 133   
Long-term pharma capitalized commissions (2)
820    798   
Total pharma capitalized commissions $ 1,003    $ 931   
Current pharma contract liabilities $ 3,570    $ 1,610   
Long-term pharma contract liabilities (3)
631    1,171   
Total pharma contract liabilities $ 4,201    $ 2,781   
(1) Current pharma contract assets and Current pharma capitalized commissions are classified as “Other current assets” on the Consolidated Balance Sheets.
(2) Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as “Other assets” on the Consolidated Balance Sheets.
(3) Long-term pharma contract liabilities are classified as “Other long-term liabilities” on the Consolidated Balance Sheets.
Summary of Disaggregation of Revenue
The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):
Three Months Ended June 30, Six Months Ended June 30,
2020 2019 2020 2019
Clinical Services:
    Client direct billing $ 45,244    $ 54,008    $ 99,535    $ 103,243   
    Commercial Insurance 15,148    20,894    37,142    41,802   
    Medicare and Medicaid 13,541    13,719    30,024    29,581   
    Self-Pay (49)   361    165    566   
Total Clinical Services $ 73,884    $ 88,982    $ 166,866    $ 175,192   
Pharma Services: 13,093    12,731    26,141    22,098   
Total Revenue $ 86,977    $ 101,713    $ 193,007    $ 197,290